Submissions from 2018
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis., Zobair M Younossi, Rohit Loomba, Mary E Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A Neuschwander-Tetri, Lawrence Serfaty, Francesco Negro, Stephen H Caldwell, Vlad Ratziu, Kathleen E Corey, Scott L Friedman, Manal F Abdelmalek, Stephen A Harrison, Arun J Sanyal, Joel E Lavine, Philippe Mathurin, Michael R Charlton, Naga P Chalasani, Quentin M Anstee, Kris V Kowdley, Jacob George, Zachary D Goodman, and Keith Lindor
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir., Zobair M Younossi, Maria Stepanova, Stuart Gordon, Stefan Zeuzem, Michael P Mann, Ira Jacobson, Marc Bourliere, Curtis Cooper, Steven Flamm, K Rajender Reddy, Kris V Kowdley, Issah Younossi, and Sharon Hunt
Submissions from 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection., Marc Bourlière, Stuart C Gordon, Steven L Flamm, Curtis L Cooper, Alnoor Ramji, Myron Tong, Natarajan Ravendhran, John M Vierling, Tram T Tran, Stephen Pianko, Meena B Bansal, Victor de Lédinghen, Robert H Hyland, Luisa M Stamm, Hadas Dvory-Sobol, Evguenia Svarovskaia, Jie Zhang, K C Huang, G Mani Subramanian, Diana M Brainard, John G McHutchison, Elizabeth C Verna, Peter Buggisch, Charles S Landis, Ziad H Younes, Michael P Curry, Simone I Strasser, Eugene R Schiff, K Rajender Reddy, Michael P Manns, Kris V Kowdley, and Stefan Zeuzem
An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis., Blaire E Burman, Manan A Jhaveri, and Kris V Kowdley
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients., M P Curry, E B Tapper, B Bacon, D Dieterich, S L Flamm, L Guest, K V Kowdley, Y Lee, S Milligan, N Tsai, Z Younossi, and N H Afdhal
Differences in hepatic expression of iron, inflammation and stress-related genes in patients with nonalcoholic steatohepatitis., Priya Handa, Akhila L Vemulakonda, Bryan D Maliken, Vicki Morgan-Stevenson, James E Nelson, Barjinder K Dhillon, Kelly A Hennessey, Rohit Gupta, Matthew M Yeh, and Kris V Kowdley
Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease., Christine C Hsu, Erik Ness, and Kris V Kowdley
New developments in the treatment of primary biliary cholangitis - role of obeticholic acid., Manan A Jhaveri and Kris V Kowdley
The Natural History of Severe Acute Liver Injury., David G Koch, J L Speiser, V Durkalski, R J Fontana, T Davern, B McGuire, R T Stravitz, A M Larson, I Liou, Oren K Fix, M L Schilsky, T McCashland, J E Hay, N Murray, O S Shaikh, D Ganger, A Zaman, S B Han, R T Chung, R S Brown, S Munoz, K R Reddy, L Rossaro, R Satyanarayana, A J Hanje, J Olson, R M Subramanian, C Karvellas, B Hameed, A H Sherker, W M Lee, and A Reuben
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection., Kris V Kowdley, Vinay Sundaram, Christie Y Jeon, Kamran Qureshi, Nyan L Latt, Amandeep Sahota, Stephen Lott, Michael P Curry, Naoky Tsai, Nathorn Chaiyakunapruk, Yoori Lee, Jorg Petersen, and Peter Buggisch
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir., David Wyles, Hadas Dvory-Sobol, Evguenia S Svarovskaia, Brian P Doehle, Ross Martin, Nezam H Afdhal, Kris V Kowdley, Eric Lawitz, Diana M Brainard, Michael D Miller, Hongmei Mo, and Edward J Gane
